Alector, Inc.
Alector, Inc. (ALEC): 18 pipeline candidates · ~12 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.3 months
D/E 22.11 · 0% dilution
Lead: Phase 2
18 candidates
N/A
0 buys · 11 sells (180d)
A transparent, data-derived signal for Alector, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$173.2M
Cash
$78.8M
Quarterly Burn
$49.8M
Runway
12.3 mo
Revenue
$1.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| ADP037-ABC | Preclinical |
| ADP050-ABC | Preclinical |
| ADP056 | Preclinical |
| ADP062-ABC | Preclinical |
| ADP063-ABC | Preclinical |
| ADP064-ABC | Preclinical |
| ADP065-ABC | Preclinical |
| AL001 | Phase 2 |
| AL002 | Phase 2 |
| AL037 | Preclinical |
Showing 10 of 18 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$147.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,741,245 | $16.6M |
| vanguard capital management llc | 7,357,444 | $15.8M |
| d. e. shaw & co., inc. | 3,332,835 | $7.2M |
| 683 capital management, llc | 3,200,000 | $6.9M |
| balyasny asset management l.p. | 2,935,253 | $6.3M |
| vanguard portfolio management llc | 2,583,542 | $5.6M |
| geode capital management, llc | 2,286,218 | $4.9M |
| jacobs levy equity management, inc | 2,154,361 | $4.6M |
| spruce street capital lp | 2,101,068 | $4.5M |
| ikarian capital, llc | 2,082,606 | $4.5M |
Showing top 10 of 133 institutional holders of Alector, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alector, Inc.'s pipeline?
Alector, Inc. (ALEC) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alector, Inc.'s lead drug candidate?
Alector, Inc.'s most advanced tracked candidate is ADP037-ABC (Preclinical) for Alzheimer's disease.
What is Alector, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alector, Inc. has approximately 12.3 months of cash runway.
What is Alector, Inc.'s market capitalization?
Alector, Inc.'s market capitalization is approximately $173.2M.
Who is the CEO of Alector, Inc.?
Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector, Inc. (ALEC).
Get the full picture on Alector, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.